Clinical efficacy and safety of a new 1000-mg suspension versus twice-daily 500-mg tablets of MPFF in patients with symptomatic chronic venous disorders: a randomized controlled trial

Carpentier P., van Bellen B., Karetova D., Hanafiah H., Enriquez-Vega E., Kirienko A., ...Daha Fazla

INTERNATIONAL ANGIOLOGY, cilt.36, sa.5, ss.402-409, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 36 Sayı: 5
  • Basım Tarihi: 2017
  • Doi Numarası: 10.23736/s0392-9590.17.03801-9
  • Dergi Adı: INTERNATIONAL ANGIOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.402-409
  • İstanbul Üniversitesi Adresli: Hayır

Özet

BACKGROUND: Chronic venous disorders (CVD) is estimated to affect 30% to 50% of women and 10% to 30% of men. The most widely prescribed treatment for CVD worldwide is micronized purified flavonoid fraction 500 mg (MPFF). The aim of this clinical trial was to develop a new once daily 1000-mg oral suspension of MPFF.